Compare RKT & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RKT | PTGX |
|---|---|---|
| Founded | 1985 | 2006 |
| Country | United States | United States |
| Employees | N/A | 141 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.3B | 9.3B |
| IPO Year | 2020 | 2016 |
| Metric | RKT | PTGX |
|---|---|---|
| Price | $12.02 | $136.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 13 |
| Target Price | $20.40 | ★ $108.23 |
| AVG Volume (30 Days) | ★ 26.8M | 495.1K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.19 | ★ 2.35 |
| Revenue | N/A | N/A |
| Revenue This Year | $66.40 | $874.25 |
| Revenue Next Year | $8.18 | N/A |
| P/E Ratio | $63.95 | ★ $59.02 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.11 | $62.24 |
| 52 Week High | $24.36 | $160.81 |
| Indicator | RKT | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 36.39 | 40.35 |
| Support Level | N/A | $130.63 |
| Resistance Level | $14.61 | $142.20 |
| Average True Range (ATR) | 0.48 | 4.74 |
| MACD | -0.12 | -0.99 |
| Stochastic Oscillator | 2.86 | 12.72 |
Rocket Companies is a financial services company that was originally founded as Rock Financial in 1985 and is currently based in Detroit. Rocket Companies offers a wide array of services and products but is best known for its Rocket Mortgage business. The company's mortgage lending operations are split between its direct-to-consumer lending, which sees borrowers accessing the company's lending arm directly through either its mobile app or website, and its partner network where mortgage brokers and other firms use Rocket's origination process to offer loans to their customers. The company has rapidly gained market share in recent years and will also be the largest mortgage servicer in the US following its acquisition of the Mr. Cooper Group.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.